2-Year Results of Paclitaxel-Eluting Balloons for Femoropopliteal Artery Disease

Autor: Paolo Pantaleo, Antonio Micari, Angelo Cioppa, Paolo Rubino, Chiara Grattoni, Armando Liso, Alberto Cremonesi, Alfredo Marchese, Fausto Castriota, Giancarlo Biamino, Giuseppe Vadalà
Rok vydání: 2013
Předmět:
Male
Biocompatible
Time Factors
Percutaneous
medicine.medical_treatment
Kaplan-Meier Estimate
Disease
Quality of life
Recurrence
Surveys and Questionnaires
Medicine
Popliteal Artery
Prospective Studies
Registries
Percutaneous transluminal angioplasty
Middle Aged
Constriction
Femoral Artery
Treatment Outcome
medicine.anatomical_structure
Italy
Female
Stents
Radiology
Cardiology and Cardiovascular Medicine
Vascular Access Devices
Artery
medicine.medical_specialty
Paclitaxel
Revascularization
Peripheral Arterial Disease
Angioplasty
Humans
Ankle Brachial Index
Drug-eluting balloon
Adverse effect
Vascular Patency
Aged
Pathologic
Peripheral artery disease
business.industry
Coated Materials
Cardiovascular Agents
Surgery
Amputation
Exercise Test
Quality of Life
business
Angioplasty
Balloon
Constriction
Pathologic
Coated Materials
Biocompatible
Balloon
Zdroj: JACC: Cardiovascular Interventions. 6:282-289
ISSN: 1936-8798
Popis: Objectives This study aimed to appraise 2-year outcomes after percutaneous treatment of femoropopliteal artery disease with paclitaxel-eluting balloons. Background Percutaneous transluminal angioplasty with paclitaxel-eluting balloons for femoropopliteal artery disease has provided favorable 1-year results. Methods Consecutive patients with Rutherford class 2 to 4 disease due to femoropopliteal lesions ≤15 mm long and with 3- to 7-mm reference vessel diameter were prospectively enrolled in a multicenter registry. Endpoints of interest included primary patency, major adverse events (the composite of death, amputation, or target lesion revascularization), changes in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life after ≥24 months. Results A total of 105 patients (114 lesions) treated with paclitaxel-eluting balloons and provisional stenting were enrolled, and final procedural success was obtained in all. Follow-up after 27 ± 3 months was obtained in 98 (93.3%) patients, showing that primary patency was maintained in 71 (72.4%), and major adverse events had occurred in 17 (17.5%), with persistently significant benefits in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life (all p Conclusions PEBs are associated with favorable functional and clinical outcomes at 2 years in patients with femoropopliteal artery disease requiring percutaneous revascularization.
Databáze: OpenAIRE
Externí odkaz: